A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04153929 |
|
Recruitment Status :
Completed
First Posted : November 6, 2019
Results First Posted : November 29, 2022
Last Update Posted : November 29, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight.
Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes.
During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 | Drug: BI 456906 Drug: Placebo Drug: Semaglutide | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 413 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | The trial has a double blind design within each dose group. Patients, investigators and everyone involved in trial conduct or analysis or with any other interest in this trial will remain blinded with regard to the randomized treatment assignments until after database lock. The semaglutide group is open label. |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II, Randomized, Parallel Group, Dose-finding Study of Subcutaneously Administered BI 456906 for 16 Weeks, Compared With Placebo and Open-label Semaglutide in Patients With Type 2 Diabetes Mellitus. |
| Actual Study Start Date : | April 30, 2020 |
| Actual Primary Completion Date : | October 8, 2021 |
| Actual Study Completion Date : | November 4, 2021 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: BI 456906 0.3 mg |
Drug: BI 456906
Solution for Injection |
| Experimental: BI 456906 0.9 mg |
Drug: BI 456906
Solution for Injection |
| Experimental: BI 456906 1.8 mg |
Drug: BI 456906
Solution for Injection |
| Experimental: BI 456906 2.7 mg |
Drug: BI 456906
Solution for Injection |
| Experimental: BI 456906 1.2 twice weekly (2.4) mg |
Drug: BI 456906
Solution for Injection |
| Experimental: BI 456906 1.8 twice weekly (3.6) mg |
Drug: BI 456906
Solution for Injection |
| Active Comparator: Semaglutide |
Drug: Semaglutide
Solution for Injection |
| Placebo Comparator: Placebo |
Drug: Placebo
Solution for Injection |
- Absolute Change in HbA1c From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start). ]
Absolute change in glycosylated hemoglobin A1c (HbA1c) from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17.
Absolute change from baseline in HbA1c to 16 weeks after treatment start was calculated by subtracting the baseline HbA1c value from the HbA1c value at Week 17.
- Key Secondary Endpoint: The Relative Change in Body Weight From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start ). ]
The relative change in body weight from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17.
The relative change in body weight from baseline to 16 weeks after treatment start was calculated as (body weight at Week 17 - body weight at baseline/body weight at baseline) * 100.
- The Absolute Change in Body Weight From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start). ]
The absolute change in body weight from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
The absolute change in body weight from baseline to 16 weeks after treatment start was calculated as: body weight at Week 17- body weight at baseline.
- The Absolute Change in Waist Circumference From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start). ]
The absolute change in waist circumference from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
The absolute change in waist circumference from baseline to 16 weeks after treatment start was calculated as: waist circumference at Week 17- waist circumference at baseline.
- Percentage of Patients With 5 % or Greater Body Weight Loss From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start). ]
The percentage of patients with 5 percent (%) or greater body weight loss from baseline to 16 weeks after treatment start is presented.
Measurements for this outcome were performed at baseline and at Week 17.
- Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks [ Time Frame: At baseline and at Week 17 (16 weeks after treatment start). ]
The percentage of patients with 10 % or greater body weight loss from baseline to 16 weeks after treatment start is presented.
Measurements for this outcome were performed at baseline and at Week 17.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Signed and dated written informed consent in accordance with International conference on harmonization - Good clinical practice (ICH GCP) and local legislation.
- Male and female patients 18 years to 75 years (both inclusive) of age on the day of signing informed consent.
- Diagnosis of Type 2 diabetes mellitus (T2DM) at least 6 months prior to informed consent.
- Glycosylated hemoglobin A1c (HbA1c) 7.0%-10.0% (both inclusive) at screening.
- Treatment with a stable dose of metformin ≥ 1000mg/day for at least 3 months prior to screening.
- Body mass index (BMI) 25 kg/m2-50 kg/m2 (both inclusive) at screening.
- Women of childbearing potential must be ready and able to use highly effective methods of birth control.
Exclusion criteria:
- Patients with type 1 diabetes.
- Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists (including combination products) within 3 months prior to screening, or any previous exposure to BI 456906.
- Any additional oral anti-hyperglycemic medication beyond metformin within 3 months prior to screening.
- Use of insulin for glycemic control within 12 months prior to screening.
- Resting Heart Rate >100 bpm or blood pressure ≥160/95 mmHg at screening.
- A marked baseline prolongation of QT/QTc (Fridericia) interval or any other clinically significant Electrocardiogram (ECG) finding at screening.
- Body weight change of +/- 5% or more in the past 3 months or on anti-obesity therapies at any time during the 6 months prior to screening.
-
Continuous oral pharmacotherapy to treat any clinical condition during the Trial. Following medications are allowed:
- metformin, anti-hypertensives (any medication known to cause heart block or bradycardia such as beta-blockers, verapamil and diltiazem are excluded unless used to treat heart rate control or hypertension),
- Hormone replacement therapy including thyroid hormone, lipid lowering, proton pump inhibitors, H2 blockers for Gastric esophageal reflux disease (GERD), analgesics,
- sleep medications
- antihistamines
- selective Alpha receptor blocker for benign prostatic hyperplasia Patients must be on a stable dose for at least 3 months Prior to Screening
- Any suicidal behavior in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-suicide severity rating scale (C-SSRS) in the past 3 months at screening.
- Chronic or relevant acute infections.
- Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
- Further exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04153929
Show 80 study locations
Documents provided by Boehringer Ingelheim:
| Responsible Party: | Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT04153929 |
| Other Study ID Numbers: |
1404-0002 2019-002390-60 ( EudraCT Number ) |
| First Posted: | November 6, 2019 Key Record Dates |
| Results First Posted: | November 29, 2022 |
| Last Update Posted: | November 29, 2022 |
| Last Verified: | November 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
| Time Frame: | After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication. |
| Access Criteria: | For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'. |
| URL: | https://www.mystudywindow.com/msw/datasharing |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |